This document discusses the perioperative management of diabetic patients. It begins with definitions and statistics on diabetes prevalence worldwide. It then covers diagnostic criteria, physiology of glucose metabolism, complications of diabetes, and pre-anesthetic evaluation of diabetic patients. The document discusses the metabolic response to anesthesia and surgery in diabetics and goals and methods for achieving glycemic control in the perioperative period. It also addresses anesthetic techniques for diabetics and potential medical/legal pitfalls in their management.
Perioperative management of a patient with diabetes mellitusrajkumarsrihari
Anesthetic implications in a patient with Diabetes Mellitis with latest updates taken from british journal of anesthesia on perioperative glycemic control (2013)
DM is a metabolic disorder with an increasing global incidence and prevalence. Poor peri-operative glycaemic control increases the risk of adverse outcomes. Through careful glycemic management in perioperative period, we may reduce morbidity and mortality and improve surgical outcomes.
Perioperative management of a patient with diabetes mellitusrajkumarsrihari
Anesthetic implications in a patient with Diabetes Mellitis with latest updates taken from british journal of anesthesia on perioperative glycemic control (2013)
DM is a metabolic disorder with an increasing global incidence and prevalence. Poor peri-operative glycaemic control increases the risk of adverse outcomes. Through careful glycemic management in perioperative period, we may reduce morbidity and mortality and improve surgical outcomes.
Perioperative management of diabetes mellitusSourav Mondal
A detailed stepwise approach for the perioperative management of diabetes mellitus.
Sources taken from latest edition of Harrison, Millers, Stoeltings and ADA Guidelines.
By a anaesthetist, for a anaesthesist
DIABETES AND ITS ANAESTHETIC IMPLICATIONSSelva Kumar
This presentation deals with diabetes mellitus and its anaesthetic implications. All about preoperative investigations and intra-operative management are discussed.
diagnosis & complication of Diabetes mellitus including Diabetic ketoacidosis & HHS
anaesthesia managment for patient with DM posted for surgery both emergency and elective surgery
gestational diabetes mellitus
Diabetes in surgery (evidence based management protocol)Hriday Ranjan Roy
25% diabetic patient need surgery. He or she may have surgical disease along with diabetes or diabetes may complicate to surgical conditions. So it is critical to manage diabetes during surgical events.
Perioperative management of diabetes mellitusSourav Mondal
A detailed stepwise approach for the perioperative management of diabetes mellitus.
Sources taken from latest edition of Harrison, Millers, Stoeltings and ADA Guidelines.
By a anaesthetist, for a anaesthesist
DIABETES AND ITS ANAESTHETIC IMPLICATIONSSelva Kumar
This presentation deals with diabetes mellitus and its anaesthetic implications. All about preoperative investigations and intra-operative management are discussed.
diagnosis & complication of Diabetes mellitus including Diabetic ketoacidosis & HHS
anaesthesia managment for patient with DM posted for surgery both emergency and elective surgery
gestational diabetes mellitus
Diabetes in surgery (evidence based management protocol)Hriday Ranjan Roy
25% diabetic patient need surgery. He or she may have surgical disease along with diabetes or diabetes may complicate to surgical conditions. So it is critical to manage diabetes during surgical events.
The questions asked in the Anaesthesiology viva examination are presented in this presentation which will be useful for the post-graduates appearing for the M.D-Anaesthesia examination.
I was recently invited to visit an academic anesthesiology department to speak to the residents about becoming a leader. In addition to recognizing the honor and privilege of addressing this important topic with the next generation of physician anesthesiologists, I had two other initial thoughts: 1) I must be getting old; and 2) This isn’t going to be easy.
I came up with a short list of lessons that I’ve learned over the years. While some examples I included are anesthesiology-specific, the lessons themselves are not. Please feel free to edit, adapt, and add to this list; then disseminate it to the future physician leaders who will one day take our places.
predictors of mortality in mechanically ventilated patients using APACHE II a...Raj Mehta
A study to evaluate predictors of mortality in mechanically ventilated patients by using APACHE II and SAPS II scoring systems in adult ICU of AIIMS, New Delhi.
Severity of illness scoring systems have been developed to evaluate delivery of care and provide prediction of outcome of groups of critically ill patients who are admitted to the intensive care units. This prediction is achieved by collating routinely measured data specific to the patient. This article reviews the various commonly used ICU scoring systems, the characteristics of the ideal scoring system, the various methods used for validating the scoring systems.
Preoperative preparation of diabetes patientDrkabiru2012
Academic presentation during junior residency rotation at Anaesthesia Department of Aminu Kano Teaching Hospita Kano, by
Dr Kabiru SALISU
kbmed2003@yahoo.com
Percutaneus coronary intervention in Non ST elevation myocardial infarctionRamachandra Barik
Unstable angina (UA), acute non-ST elevation myocardial infarction (NSTEMI), and acute ST elevation myocardial infarction (STEMI) are the three presentations of acute coronary syndromes (ACS). The first step in the management of patients with ACS is prompt recognition, since the beneficial effects of therapy are greatest when performed soon after hospital presentation. For patients presenting to the emergency department with chest pain suspicious for an ACS, the diagnosis of myocardial infarction can be confirmed by the electrocardiogram (ECG) and serum cardiac biomarker elevation; the history is relied upon heavily to make the diagnosis of unstable angina
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
3. Outline
• Pre - anaesthetic evaluation
• Problems faced by a diabetic for surgery
• Goals and methods of achieving periop glycemic control
• Anaesthetic technique and the diabetic patient
• Medical / legal pitfalls
4. DEFINITION
• Diabetes mellitus is defined as a syndrome
characterized by sustained hyperglycemia
due to insulin deficiency, impaired insulin
action or a combination of both.
5. Recent statistics
• Diabetes currently affects 246 million people worldwide and is
expected to affect 380 million by 2025.
• In 2007, the five countries with the largest numbers of people
with diabetes are
• India (40.9 million)
• China (39.8 million)
• United States (19.2 million)
• Russia (9.6 million)
• Germany (7.4 million).
6. Recent statistics
• Each year 3.8 million deaths are attributable to DM.
• Cardiovascular disease is the major cause of death in
diabetes, accounting for some 50% of all diabetes
fatalities, and much disability.
• Every 10 seconds a person dies from diabetes-
related causes.
9. • Type 1 DM :
– absolute insulin deficiency,
– unopposed catabolic action leads to
hyperglycemia and diabetic ketoacidosis.
• Type 2 DM:
– peripheral resistance to insulin,
– less susceptible to developing ketoacidosis.
10. • Mortality / morbidity rates in diabetics have been
estimated to be up to 5 times greater than in
nondiabetics
Related to the end-organ damage.
12. • DM is an independent predictor of postop
myocardial ischemia and infectious
complications in patients undergoing surgery.
• The ultimate goal in the management of
diabetic patients is to achieve equivalent
outcomes as those patients without DM.
13. • A strong grasp of the complexities of glucose
insulin interrelationship and of the effects of
anesthesia and surgery is essential to optimal
management and outcomes.
14. PHYSIOLOGY OF
GLUCOSE METABOLISM
• Glucose metabolism is largely a function of the
liver, the pancreas, and, to a lesser degree,
peripheral tissue.
• Role of liver in glucose regulation:
• Extracts glucose
• Stores it in the form of glycogen
• Performs gluconeogenesis
• Glycogenolysis.
15. • Pancreas secretes counterregulatory hormones:
– Insulin from islet beta cells, which lowers blood glucose
concentrations.
– Glucagon from islet alpha cells, which raises blood
glucose concentrations.
16. • Additional contributors to glucose metabolism
include the catabolic hormones: epinephrine,
glucocorticoids, and growth hormone, which all
raise blood glucose concentrations.
• Peripheral tissues participate in glucose
metabolism by extracting glucose for energy
needs, thus lowering blood glucose levels.
17. PREOPERATIVE ASSESSMENT
• Suggestive symptoms - polyuria/polydipsia, blurred vision
• Current Rx of diabetes, including medication
regimen, diet, and glucose monitoring results
• Frequency, severity, and etiology of acute
complications (ketoacidosis / hypoglycemia)
18. • Prior or current infections (eg, skin, foot, dental, genitourinary)
• Symptoms and treatment of chronic eye; kidney; nerve;
genitourinary, bladder, and GI function; heart; peripheral
vascular; foot; and cerebrovascular complications
• Nondiabetic medications that may affect blood glucose
levels (eg, corticosteroids)
19. Preanaesthetic evaluation
• Severity and type of the diabetic state
• Anti-diabetic Medications
• Control of blood sugar
• Treatment regimens used
• Associated complications of DM
• Airway assessment
• Comorbid conditions
21. Autonomic neuropathy
• Most commonlya distal symmetrical sensory
polyneuropathywith a variable degree of
autonomic involvement.
• Autonomicdysfunction, which is of particular
importance to the anaesthetist,is detectable in up
to 40% of type 1 and 17% of type 2 diabetic
patients
22. Pathogenic mechanisms for ANP
• Local ischaemia,
• Tissue accumulationof sorbitol
• Altered function of neuronal Na+
/K+
-ATPase activity
• Immunologically mediated damage
23. • Diabetic gastroparesis is characterized by a
delay in gastricemptying without any
gastric outlet obstruction.
• The increasedamount of gastric contents
enhances the risk of acid aspirationduring
the induction of anaesthesia
24. Fundoscopic examination
• Gives insight into
the patient's risk
of developing
postop blindness,
especially
following major
prolonged
surgery.
25. stiff joint” syndrome,
• Significant risk during airway management.
• Affects temporomandibular, atlantooccipital, and
other cervical spine joints.
• Short stature and waxy skin.
Related to chronic hyperglycemia and nonenzymatic
glycosylation of collagen and its deposition in joints.
26. • A positive “prayer sign” can be
elicited on examination with the
patient unable to approximate the
palmar surfaces of the phalangeal
joints while pressing their hands
together;
• Represents cervical spine immobility
and the potential for a difficult
endotracheal intubation .
27. • Further airway evaluation should
include assessment of thyroid
gland size, as patients with type 1
DM have a 15% association of
other autoimmune diseases, such
as Hashimoto thyroiditis and
Graves disease.
28. • The degree of preoperative neurological
dysfunction is important to document, especially
prior to regional anesthesia or peripheral nerve
blocks, to assess the degree of subsequent
nerve injury.
30. • Studies have shown a correlation between preop
proteinuria and postop death after CABG, with
the mortality rate increasing proportionally with
the concentration of protein in the urine.
31. • Based on the nature of surgery, ECG assessing
R-R interval during respiration may be useful in
the evaluation of autonomic neuropathy.
Loss of R-R variability when the HR at maximal
inspiration is compared with the HR at maximal
expiration implies the presence of autonomic cardiac
neuropathy.
32. GENERAL PREOP MANAGEMENT
• On the day of surgery, patients on oral
regimens should be advised to discontinue
these medications.
Sulfonylureas, meglitinides have the potential
to cause hypoglycemia.
33. • Sulfonylureas have been associated with
interfering with ischemic myocardial
preconditioning and may theoretically
increase risk of perioperative myocardial
ischemia and infarction.
34. • Patients taking metformin should be
advised to discontinue this drug
because of the risk of developing lactic
acidosis.
35. • For these patients, short-acting insulin may
be administered s/c as a sliding scale or as a
continuous infusion,to maintain optimal
glucose control, depending on the extent of
surgery.
36. • Patients who are insulin-dependent (type 1)
should be advised to reduce their bedtime
dose of insulin the night prior to surgery to
prevent hypoglycemia, while NBM.
37. Problems faced by a diabetic for
surgery
• Surgical stress response with catabolichormone secretion
• NBM, which maybe prolonged following GI procedures
• Alteredconsciousness - masks the symptoms of
hypoglycaemia
• Circulatorydisturbances - whichmay alter the absorption of
s/c insulin.
38. METABOLIC RESPONSE TO
ANESTHESIA AND SURGERY
• Surgery induces a considerable stress response
mediated by the neuroendocrine system through the
release of catecholamines, glucagon, and cortisol.
• The principal mechanism lies with the elevation of
sympathetic tone with a subsequent release of
cortisol and catecholamines during surgery.
39. • A nondiabetic patient is able to maintain glucose
homeostasis by secreting a corresponding
amount of insulin to balance the glucose
generated by the stress response.
40. • This compensatory mechanism in diabetic
patients is impaired through a relative insulin
deficiency (type 2) or absolute insulin deficiency
(type 1) necessitating supplementation of
insulin in the perioperative period.
41. • Anesthetic agents can affect glucose metabolism
through the modulation of sympathetic tone; in vitro
evidence suggests that inhalational agents suppress
insulin secretion.
• The resulting relative insulin deficiency often leads
to glucose dysregulation and hyperglycemia.
42. • The use of regional anesthesia or peripheral
nerve blocks may mitigate these concerns,
but no data suggest that these forms of
anesthesia will improve postoperative survival
in patients with DM.
43. GOALS OF PERIOPERATIVE
GLYCEMIC CONTROL
• The goals for glycemic control are tailored to
each patient based on:
• Nature of surgery,
• Severity of underlying illness,
• Modality used to achieve glycemic control
• Patient age,
• Sensitivity to insulin.
44. • Prior to elective surgery, it is ideal for patients
to have their HbA1c < 6%.
• Less intensive glycemic control may be
indicated in patients with severe or frequent
episodes of hypoglycemia.
46. • Intravenous insulin is the most flexible and
readily titratable agent, with few, if any,
contraindications, making it an ideal agent for
perioperative use.
47. • The length, type of surgery, and degree of
glycemic dysregulation will dictate the degree
of supplemental intravenous insulin therapy.
• Patients with type 1 diabetes should have
elective surgeries scheduled as the first case
of the day to minimally disrupt their DM
regimen.
48. • Administer half of their daily dose of long-
acting insulin.
• Arrive at the preop admitting area early
enough to have an I.v infusion of dextrose
instituted and their serum glucose monitored
until the time of surgery.
49. • Establish separate iv access for a “piggyback”
infusion of regular insulin .
• The infusion rate can be determined by using the
formula: insulin (U/h) = serum glucose (mg/dL)/150.
• Intravenous glucose solution should be administered
concomitantly to avoid hypoglycemia.
50. • Typically, a 5% D solution is started when
serum glucose levels are less than 150 mg/dL.
51. • Patients suspected of gastroparesis should
receive a prokinetic drug prior to general
anesthesia to decrease the incidence of
gastric acid aspiration.
52. • Aseptic technique is critical for all procedures
in patients with DM to decrease the incidence
of postoperative infection.
• Temperature control is also essential in
patients with DM, as hypothermia can lead to
peripheral insulin resistance, hyperglycemia,
deceased wound healing, and infection.
53. • Intraop management of intravascular volume
may require the use of a central venous
pressure catheter, a pulmonary artery
catheter, or TEE to best guide therapy and to
protect against end-organ hypoperfusion.
54. • Arterial blood gas analysis should not only
include assessment of blood glucose levels
but also levels of sodium, potassium, and
assessment of pH.
55. • Type 1 diabetic patients are predisposed to
developing ketoacidosis during periods of
major stress; therefore, they should be
monitored by arterial blood gas analysis
during and after major surgery.
56. General guidelines for periop control
of diabetes
• Check blood glucose, urea, electrolytes and urinary
ketones
• Adjust insulin therapy BD – soluble isophane insulin
• Poor control: change to TID – soluble insulin and delay
elective surgery
• Urgent surgery: glucose insulin infusion
57. Day of surgery
• Check fasting sugar
• No subcutaneous insulin
• Start 10% D (500ml) with 10 U human insulin and KCI
1Ommol for 4-6 h
• Adjust insulin according to the blood sugar values
<4 No insulin
4-6 Insulin 5 U / 500 mL 10%glucose
6-10 Same as above
10-20 15 U/ 500 Ml 10% glucose
>20 20 U/500 mL 10%glucose
58. • K+ is adjusted according to serum K+
K+<3 mmol/L add 20 mmol K+/500 ml
K+>5 mmol/L no KCI
59. Postop major surgery
• Check blood sugar every 2-6 h
• Check urea, electrolytes every 4-6h
• Continue infusion till oral feeding is established
• If feeding is delayed, change to 20% glucose with less
volume
• When oral diet is established, q8h soluble insulin prior to
each feed
• When insulin requirements are stable,restart the
preoperative regimen
60. Emergency surgery and DKA
• DKA results from inadequate insulin dosage
or increased insulin requirement often
precipitated by trauma, infection or surgical
stress.
• Administer insulin at the rate of 4-8U/hr,
depending on factors such as blood sugar
levels, ketosis and acidosis.
61. • Correct dehydration, sodium depletion and
subsequent potassium depletion
• Replace fluids with isotonic solution of NaCI 1 L in 30
min,1 L in the next hour and further 1 L over the next
2 hours.
• Monitor blood glucose levels, arterial pH and blood
gases
• K+may be normal or elevated due to presence of
acidosis
62. • Magnesium 5-10 mmol is also required along with K+
depletion.
• 5% D can be started when blood glucose decreases
to 15 mmol/L
• Surgery is ideally carried out after reversal of acidosis and
hyperglycemia.
• However, if the indication for surgery is emergent, surgery
can be started when volume resuscitation is underway,
with the diabetic management being continued in the
intraop and postop periods.
63. Tight control of blood glucose
• Tight control of blood sugar between 80 – 120 mgs/dL
– Prevents ischemia
– Improves wound healing
– Improves weaning from CPB
64. REGIMEN - 1
• Preprandial sugar levels on the evening before
surgery.
• Start infusion of 5% D at the rate of 50 ml/hr
• To this infusion, piggyback regular insulin 50 U in
250 ml 0.9 Nacl.
• Set the infusion rate U/hr = Plasma glucose
150
65. REGIMEN - 1
• Repeat glucose values q4h, and adjust insulin infusion
to achieve plasma glucose of 100-200 mg/dl.
• Intraop - use non dextrose containing fluids.
• Determine plasma glucose q2h and adjust insulin
accordingly.
• Serum K+ should be checked and adjusted accordingly
with particular care for poor renal function.
66.
67.
68. Anaesthetic technique and the
diabetic patient
• Regional blockade, may modulate the secretionof
the catabolic hormones and any residual insulin
secretion.
• The periop increase in circulating glucose,
epinephrineand cortisol concentrations found in
non-diabetics exposedto surgical stress under GA
is blocked by epiduralanaesthesia
69. • The perioperative infusion of phentolamine,a
competitive -adrenergic receptor blocking drug,
decreasesthe glycaemic response to surgery by
partially reversing thesuppression of insulin
secretion
70. • Regional anaesthesia may carry greater
risks in the diabeticpatient with autonomic
neuropathy.
• Profound hypotension mayoccur with
deleterious consequences in a patient with
co-existingcoronary artery, cerebrovascular
or renovascular disease
71. Medical / Legal Pitfalls
• Overtreatment or undertreatment of hypoglycemia,
eg, premature discharge of a patient who develops
hypoglycemia due to a sulfonylurea agent, is a pitfall.
• Failure to record the blood glucose levels of patients
with wounds or active infections when they are <250
mg/dL is a pitfall and may lead to poor healing.
72. Medical / Legal Pitfalls
• Failure to provide adequate hydration to patients
with mild diabetic nephropathy before contrast
material is given may precipitate acute renal failure.
• Failure to examine the patient's feet and failure to
detect small ulcers or underestimation of their
seriousness are also pitfalls.
• Failure to consider myocardial ischemia in patients
with nonspecific symptoms is a pitfall.
73. Conclusions
• There have been major advances in the last few years in
understanding and treating complications of diabetes.
• The main focus has been on good glycemic control.
• The incidence of diabetes is on the rise in most
populations, with Indians being more prone to develop
diabetes.
74. • Diabetes mellitus is likely to be the most common
comorbid factor encountered in Surgical practice.
• A clear understanding of the metabolic process, well
controlled glycemic regimens and excellent periop
care will go a long way towards decreasing the
mortality and morbidity in diabetes patients.